Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02121600
Previous Study | Return to List | Next Study

18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02121600
Recruitment Status : Terminated (Low accrual)
First Posted : April 23, 2014
Last Update Posted : May 7, 2019
Sponsor:
Collaborator:
OICR
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:

Evaluate the ability of 18F-FCH PET/MRI scan to detect pre-treatment tumor burden and assess response to treatment in men with castration resistant prostate cancer (CRPC).

It is hypothesized that these novel biomarkers will better identify evaluable lesions prior to therapy and identify response to treatment (or lack thereof) earlier in the treatment period, providing a better guide for treating men with CRPC.


Condition or disease Intervention/treatment Phase
Prostate Cancer Other: [F-18]-FCH Radiation: PET scan Radiation: MRI scan Not Applicable

Detailed Description:

Castrate resistant prostate cancer (CRPC) occurs when prostate cancer no longer responds to androgen deprivation therapy. Eventually all men diagnosed with CRPC will succumb to their disease. While many new therapies have been introduced, there are limitations in assessing treatment response and physicians are faced with a challenge when creating a management strategy for men with CRPC.

Most men present with bone metastases, and accurate quantification of disease burden can be difficult due to the nature of conventional scans such as CT and bone scan. In addition, the standard blood PSA measurement does not always reflect a clinical response, or may lag to show this response. There is a clear need for better imaging and blood biomarkers to measure disease in men with CRPC.

This study will explore the benefit of a 18F-FCH Hybrid PET/MRI scan, Cancer Microparticle (CMP) and Circulating Tumor Cell (CTC) measurements compared to standard imaging and PSA levels.

In this study, patients will receive a 18F-FCH PET/MRI or 18F-FCH PET/CT scan + whole body MRI at baseline and after 12 weeks of treatment. Serial CMP and CTC blood samples will be taken at 5 study timepoints.

66 patients will be enrolled at 3 cancer centres in Ontario. Patients will be divided into 2 cohorts based on the type of treatment they will receive: Docetaxel or Abiraterone.

It is hypothesized that these novel biomarkers will better identify evaluable lesions prior to therapy and identify response to treatment (or lack thereof) earlier in the treatment period thus providing a better guide for treating men with CRPC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Assessment of CRPC Response Through Comprehensive Characterization Using Novel Biomarkers (PET CRPC)
Study Start Date : September 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : March 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Docetaxel
Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan
Other: [F-18]-FCH
Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
Other Name: [F-18]-Fluorocholine Injection

Radiation: PET scan
A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment

Radiation: MRI scan
Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment

Abiraterone
Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan.
Other: [F-18]-FCH
Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
Other Name: [F-18]-Fluorocholine Injection

Radiation: PET scan
A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment

Radiation: MRI scan
Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment




Primary Outcome Measures :
  1. Number of lesions detected with 18F-FCH PET/MRI compared to conventional imaging [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Number of concordant lesions identified on identified on 18F-FCH PET, conventional imaging and MRI [ Time Frame: 3 years ]
  2. Concordance between number Circulating Tumor Cells (CTCs) and Cancer Microparticles (CMPs) and number of lesions detected by PET/MRI and conventional imaging [ Time Frame: 3 years ]
    At both baseline and after 12 weeks of treatment

  3. Change in number and size of lesions after 12 weeks of treatment [ Time Frame: 3 years ]
    As detected by 18F-FCH PET/MRI and change in CTC and CMP values

  4. Progression Free Survival [ Time Frame: 6 years ]
    Changes in lesion parameters on PET and MRI and changes in serial CTC and CMP levels will be assessed to see if they are predictive of progression free survival

  5. Overall Survival [ Time Frame: 6 years ]
    Changes in lesion parameters on PET and MRI and changes in serial CTC and CMP levels will be assessed to see if they are predictive of overall survival


Other Outcome Measures:
  1. Percentage of change in clinical management based on results of 18F-FCH PET/MRI and CTC results [ Time Frame: 3 years ]
  2. Concordance of identified lesions on hybrid PET/CT + fused MRI vs hybrid PET/MRI [ Time Frame: 3 years ]
  3. Concordance between CTC values on a new microfluidics-based CTC assay and the FDA/Health Canada approved CellSearch CTC assay (clinical gold standard) [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Patient with CRPC and experiencing disease progression as defined by PCWG2
  • ECOG 0-2
  • Must continue gonadal castrative therapy
  • Has completed antiandrogen withdrawal ≥ 6 weeks prior to registration
  • Metastatic disease documented by imaging
  • Patient is planned for treatment with docetaxel or abiraterone
  • If treated with bisphosphonates or denosumab, has been on these for ≥ 6 weeks.
  • Must provide written informed consent

Exclusion Criteria:

  • Prior history of invasive malignant disease unless disease free for at least 5 years, with the exception of non-melanoma skin cancer
  • Planned for any concurrent anticancer treatment oher than docetaxel or abiraterone
  • Prior radiotherapy or surgery within 4 weeks of start of docetaxel or abiraterone
  • Inability to comply with the imaging requirements (eg. inability to lie supine for one hour)
  • Allergy to MRI contrast agent or PET tracer to be used as part of the imaging
  • Sickle cell disease or other hemoglobinopathies
  • Insufficient renal function (eGFR ≤ 30 mL/min)
  • Known residual bladder volume > 150 cc
  • Hip prosthesis or intrabdominal vascular grafting
  • Contraindication to CT contrast
  • Contraindication to MRI as per institutional policy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02121600


Locations
Layout table for location information
Canada, Ontario
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Lawson Health Research Institute
OICR
Investigators
Layout table for investigator information
Principal Investigator: Eric Winquist, MD London Health Sciences Centre
Layout table for additonal information
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT02121600    
Other Study ID Numbers: PET CRPC
First Posted: April 23, 2014    Key Record Dates
Last Update Posted: May 7, 2019
Last Verified: May 2019
Keywords provided by Lawson Health Research Institute:
Fluorocholine (FCH)
Positron Emission Tomography (PET)
Magnetic Resonance Imaging (MRI)
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases